Is Margituximab/Meganex available in China?

Margetuximab is an innovative monoclonal antibody drug for HER2-positive breast cancer . It is mainly used to treat patients whose disease has progressed despite previous trastuzumab treatment. Its unique Fc segment modification design can enhance binding to immune effector cells, thereby improving antibody-dependent cellular cytotoxicity (ADCC), providing a new treatment option for patients with HER2-positive breast cancer.

As of 2025, margetuximab has not yet been officially approved for marketing in China. In overseas markets, especially the United States and some European countries, Meganex has been used in patients with metastatic or advanced HER2-positive breast cancer who have previously received trastuzumab treatment, and has shown considerable efficacy and safety. If domestic patients want to use it, they currently mainly rely on international clinical trial channels or obtain it through special import channels. However, these methods have certain restrictions and approval processes, and are not suitable for large-scale clinical use.

China's clinical drug regulatory system has strict requirements for the launch of new monoclonal antibody drugs, including complete clinical trial data, drug quality assessment and safety monitoring. Since magituximab is a biological agent with a long development and approval cycle, the domestic launch time has not yet been determined. However, as the demand for treatment of HER2-positive breast cancer increases and multinational pharmaceutical companies accelerate the establishment of clinical research and registration applications in China, it is expected to be approved in the next few years. For domestic patients, paying close attention to official drug approval information and guidance from professional oncologists is the safest way.

In general, margituximab is still not on the market in China, but its successful experience in the international market and unique mechanism of action have brought new hope to domestic patients with HER2-positive breast cancer.

Reference materials:https://www.margenza.com/